Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with Chemoradiation in Stage III NSCLC (PACIFIC2)
NCT03519971Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2018
- Primary completion
- Sep 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of durvalumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AstraZeneca. Primary endpoint: Progression-Free Survival at 1988 days. Started Mar 2018; status: completed.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03519971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03519971.